GleamWall
中文EN

ACIU AC Immune SA IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1651625 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-86.9%
TTM net income YoY-38.4%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR-3.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,940.1%
Net margin-1,971.6%
FCF margin-1,963.7%
EBITDA margin—

Returns

ROE-89.7%
ROA-36.6%
ROIC (approx.)-116.4%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets70.9%
Debt / equity0.00x
Current ratio1.02x
Interest coverage-362.92x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue25.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-302022Q4*2022-12-312022Q3*2022-09-302022Q2*2022-06-302021Q4*2021-12-312021Q3*2021-09-30
Income statement
Revenue1.31M687,00001,0003.93M000
R&D expense16.83M17.14M13.68M15.14M14.38M15.69M20.12M15.12M
SG&A expense3.90M4.55M3.68M3.96M3.27M4.37M2.92M5.42M
Operating income-19.39M-20.96M-17.05M-18.70M-13.46M-19.86M-22.79M-20.28M
Interest expense50,00034,00027,000-1,00077,000126,000173,000181,000
Pretax income-21.19M-22.76M-16.83M-18.75M-13.51M-19.64M-21.27M-15.92M
Income tax——3,0002,0004,0003,000——
Net income-21.19M-22.76M-16.83M-18.75M-13.52M-19.64M-21.28M-15.92M
EPS (basic)-0.21-0.23-0.20—-0.16-0.23—-0.22
EPS (diluted)-0.21-0.23-0.20—-0.16-0.23—-0.22
Weighted avg. shares (diluted)100.63M99.55M84.61M—83.59M84.46M—72.89M
Balance sheet
Cash & equivalents25.72M51.56M40.01M31.59M44.50M63.15M82.22M93.58M
Short-term investments101.41M123.56M53.00M91.00M——116.00M—
Receivables—0——————
Current assets131.81M180.54M99.15M128.09M147.60M—202.63M—
PP&E, netmay include right-of-use assets (IFRS)2.49M2.93M3.76M4.26M4.69M—5.12M—
Intangibles50.42M50.42M50.42M50.42M50.42M—50.42M—
Total assets190.22M237.53M156.23M185.94M205.56M—261.44M—
Current liabilities98.97M100.53M11.15M11.48M13.60M—20.03M—
Total liabilities115.48M114.11M16.90M16.95M15.50M—29.46M—
Shareholders' equity74.74M123.42M139.33M168.99M190.05M202.81M231.98M179.22M
Cash flow statement
Operating cash flow———-17.41M-13.54M—-17.83M—
Capital expenditure———41,000121,000—722,000—
Free cash flow———-17.45M-13.66M—-18.55M—
Investing cash flow———4.96M-5.12M—-21.72M—
Financing cash flow———-151,000-142,000—28.73M—
Stock-based compensation1.10M1.40M—889,000555,000—1.04M—

Free plan shows the latest 8 periods; Pro shows all 16 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.